Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9219063 | 0.82 | CHRNB2 (0.59) | CHRNA7 | |
| SCHEMBL24775407 | 0.81 | CHRNB2 (0.64) | ALDH1A1CHRNA7 | |
| SCHEMBL13162079 | 0.81 | CHRNB2 (0.64) | ALDH1A1CHRNA7 | |
| SCHEMBL19275748 | 0.77 | ALDH1A1 (0.49) | ALDH1A1MAOAMAOBMAPK1CHRNA7 | |
| SCHEMBL24775482 | 0.77 | RIPK1 (0.44) | ALDH1A1MAOAMAOBMAPK1CHRNA7 | |
| SCHEMBL19862549 | 0.77 | MAPK1 (0.45) | ALDH1A1MAOAMAOBMAPK1CHRNA7 | |
| SCHEMBL14945588 | 0.76 | CHRNA7 (0.57) | ALDH1A1MAOAMAOBCHRNA7 | |
| SCHEMBL11939438 | 0.73 | TP53 (0.46) | ALDH1A1MAOAMAOBCHRNA7SMN1; SMN2 | |
| SCHEMBL31318774 | 0.72 | ADAM17 (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL20843351 | 0.70 | ADAM17 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | ALDH1A1 436/4885MAOA 132/4885MAOB 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.